Recombinant ITGAL (Efalizumab Biosimilar) anticorps
-
- Antigène Tous les produits ITGAL (Efalizumab Biosimilar)
- ITGAL (Efalizumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp ITGAL (Efalizumab Biosimilar) est non-conjugé
- Application
- Blocking Reagent (BR), Flow Cytometry (FACS)
- Specificité
- Binds to human LFA-1.
- Attributs du produit
-
OriginalSpeciesName: Human
OriginalFormat: IgG1
- Purification
- Purified antibody.
- Pureté
- > 98 % as determined by SDS-PAGE
- niveau d'endotoxine
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- Immunogène
- Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes.
- Clone
- Hu1124
- Isotype
- IgG kappa
-
-
- Indications d'application
- Efalizumab binds to the LFA-1 alpha I domain blocking the ICAM-1 binding site via steric hindrance.
- Commentaires
-
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- Restrictions
- For Research Use only
-
- Buffer
- PBS with 0.02 % Proclin 300.
- Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C,-20 °C
- Stockage commentaire
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Antigène
- ITGAL (Efalizumab Biosimilar)
- Abstract
- ITGAL (Efalizumab Biosimilar) Produits
- Synonymes
- anticorps CD11A, anticorps LFA-1, anticorps LFA1A, anticorps integrin subunit alpha L, anticorps ITGAL
- Classe de substances
- Biosimilar
- Sujet
- LFA-1, integrin alpha L
- UniProt
- P20701
-